Endosense (Geneva) said it has enrolled the first patients in its ProForce Registry, marking the launch of the company's international, single arm, multi-center, post-market trial of its TactiCath force-sensing ablation catheter. The study is expected to enroll up to 2,000 patients. (Medical Device Daily) Read More
